At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Accuracy Evaluation of Glucometry Monitor Developed by Spectrophon LTD
In Brief
An observational study evaluating Spectrophon Glucometry Monitor and YSI 2300 Stat Plus for Glucose Metabolism Disorders and Diabetes Mellitus. Completed, enrolled 210 participants across 1 site.
Detailed Summary
Diabetes mellitus (or diabetes) is a chronic, metabolic disease characterized by elevated levels of blood glucose. Patients with diabetes need to monitor their blood glucose level several times a day to control their medical state. Modern biosensors have become a promising solution for non-invasive blood glucose measurements. This study aims to validate the efficacy and the accuracy of Glucometry Monitor (NIGM) developed by Spectrophon LTD incorporated in smart watches. Method Participants will use Spectrophon biosensors to non-invasively estimate the level of glucose in blood. Blood will also be collected and the glucose level will be checked with commercially available blood glucose analyzers . All sets of data will be compared to estimate the accuracy of measurements of Spectrophon NIGM
Study Details
Timeline
Interventions
Wearable smartwatch with integrated non-invasive glucose detection system
Reference commercial glucometer